Stryker Shares Fall 8% to 52-Week Low as Vascular Supply Problems Persist Into Q4

Stryker shares tumbled as much as 8.1% on Tuesday, September 8, closing near $278.71 and hitting a 52-week intraday low of $280.99, after the company disclosed that ongoing manufacturing problems in its peripheral vascular business are worse than previously expected. Chief Financial Officer Preston Wells, speaking at the Wells Fargo 21st Annual Healthcare Conference, said the supply shortfall is "not allowing us to reach a full supply of inventory at all of our customers and quite frankly, not allowing us to go out and really win new business."

Stryker had previously anticipated the manufacturing issues would be resolved in the third quarter, but Wells told conference attendees the company now expects the disruption to stretch into the fourth quarter. The peripheral vascular segment, he noted, is "not quite seeing that same recovery that we would have expected from a supply standpoint." Comments on the orthopaedics segment also weighed on sentiment, contributing to a session in which Stryker underperformed its medical technology peers.

The sell-off leaves Stryker shares down roughly 21% year to date, and the stock has now entered oversold territory according to dividend-focused ranking models that track valuation and fundamentals. The 52-week high of $396.86 was reached in September 2025, meaning shares have shed more than $110 from that peak.